콘텐츠로 건너뛰기
Merck

H1512

Haloperidol

≥98% (TLC), powder, dopamine receptor antagonist

동의어(들):

4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C21H23ClFNO2
CAS 번호:
52-86-8
Molecular Weight:
375.86
NACRES:
NA.77
PubChem Substance ID:
24277917
UNSPSC Code:
12352200
EC Number:
200-155-6
MDL number:
MFCD00051423

주요 문서

모든 문서 보기
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

제품 이름

Haloperidol, powder

InChI key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

SMILES string

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

form

powder

color

white

solubility

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL, 0.1 M HCl: 3 mg/mL, DMSO: soluble, H2O: insoluble, ethanol: soluble

originator

Johnson & Johnson

Quality Level

200

Gene Information

human ... ABCB1(5243), ADRA1A(148), ADRA2A(150), ADRA2C(152), CHRM1(1128), DRD2(1813), DRD3(1814), DRD4(1815), EBP(10682), HRH1(3269), HTR2A(3356), HTR2C(3358), HTR7(3363), KCNH1(3756), KCNH2(3757), PRNP(5621)
rat ... Adra1a(29412), Adra2a(25083), Chrm1(25229), Chrm2(81645), Drd1a(24316), Drd2(24318), Drd3(29238), Drd4(25432), Hrh1(24448), Htr1a(24473), Htr1b(25075), Htr2a(29595), Htr2c(25187), Oprs1(29336), Slc6a3(24898), Slc6a4(25553)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

Application

Haloperidol has been used:
  • in ethanol to serves as an inhibitor of Erg2p
  • to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines
  • in receptor internalization assay
  • as an antipsychotic drug in Dulbecco′s Modified Eagle medium

Biochem/physiol Actions

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

저장 등급

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number
WXBF4894V
WXBF2537V
WXBF0898V
WXBD9387V
WXBD6346V

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells
Bai T, et al.
Biochemical and Biophysical Research Communications, 491(4), 919-925 (2017)
CRC Desk Reference of Clinical Pharmacology null
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells
Jiang L, et al.
BioMed Central Pharmacology, 9(1), 6-6 (2009)
Cdk5 phosphorylates dopamine D2 receptor and attenuates downstream signaling
Jeong J, et al.
Testing, 8(12), e84482-e84482 (2013)
Yeast sphingolipids do not need to contain very long chain fatty acids
Cerantola V, et al.
The Biochemical Journal, 401(1), 205-216 (2007)
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.